Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

BIOCON vs GLENMARK PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More


Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More


Current Valuations

P/E (TTM) x 18.4 15.0 122.5% View Chart
P/BV x 2.9 2.7 108.0% View Chart
Dividend Yield % 0.4 0.4 102.1%  


5-Yr Chart
Click to enlarge
High Rs1,188930 127.7%   
Low Rs305517 58.9%   
Sales per share (Unadj.) Rs68.7322.6 21.3%  
Earnings per share (Unadj.) Rs7.628.5 26.5%  
Cash flow per share (Unadj.) Rs14.039.2 35.6%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.3 48.5%  
Book value per share (Unadj.) Rs86.3183.0 47.2%  
Shares outstanding (eoy) m600.00282.17 212.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.2 484.2%   
Avg P/E ratio x98.925.4 389.1%  
P/CF ratio (eoy) x53.418.5 289.3%  
Price / Book Value ratio x8.64.0 218.6%  
Dividend payout %13.27.0 188.6%   
Avg Mkt Cap Rs m447,900204,206 219.3%   
No. of employees `0006.113.7 44.8%   
Total wages/salary Rs m9,31118,718 49.7%   
Avg. sales/employee Rs Th6,705.86,636.8 101.0%   
Avg. wages/employee Rs Th1,514.21,364.7 111.0%   
Avg. net profit/employee Rs Th736.9586.1 125.7%   
Net Sales Rs m41,23491,031 45.3%  
Other income Rs m2,062914 225.6%   
Total revenues Rs m43,29691,945 47.1%   
Gross profit Rs m8,29116,154 51.3%  
Depreciation Rs m3,8513,019 127.6%   
Interest Rs m6152,856 21.5%   
Profit before tax Rs m5,88711,193 52.6%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5693,155 49.7%   
Profit after tax Rs m4,5318,039 56.4%  
Gross profit margin %20.117.7 113.3%  
Effective tax rate %26.728.2 94.6%   
Net profit margin %11.08.8 124.4%  
Current assets Rs m41,48669,887 59.4%   
Current liabilities Rs m21,41332,879 65.1%   
Net working cap to sales %48.740.7 119.7%  
Current ratio x1.92.1 91.1%  
Inventory Days Days6481 78.6%  
Debtors Days Days9493 100.7%  
Net fixed assets Rs m50,66128,892 175.3%   
Share capital Rs m3,000282 1,063.1%   
"Free" reserves Rs m48,80851,353 95.0%   
Net worth Rs m51,80851,635 100.3%   
Long term debt Rs m17,89841,418 43.2%   
Total assets Rs m99,897125,954 79.3%  
Interest coverage x10.64.9 214.9%   
Debt to equity ratio x0.30.8 43.1%  
Sales to assets ratio x0.40.7 57.1%   
Return on assets %5.28.6 59.6%  
Return on equity %8.715.6 56.2%  
Return on capital %9.615.1 63.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05836,317 33.2%   
Fx outflow Rs m7,3489,720 75.6%   
Net fx Rs m4,71026,598 17.7%   
From Operations Rs m6,62116,481 40.2%  
From Investments Rs m-6,840-10,133 67.5%  
From Financial Activity Rs m-2,397-4,685 51.2%  
Net Cashflow Rs m-2,6121,770 -147.6%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster


Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Today's Market

Sensex Opens Marginally Lower; IT Stocks Under Pressure(09:30 am)

Asian share markets edged near this year's peak while benchmark US treasury yields, and the dollar dropped after the Federal Reserve signaled possible interest rate cuts later this year.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Jun 20, 2019 10:21 AM